363 related articles for article (PubMed ID: 18625455)
1. Cholinergic treatments with emphasis on m1 muscarinic agonists as potential disease-modifying agents for Alzheimer's disease.
Fisher A
Neurotherapeutics; 2008 Jul; 5(3):433-42. PubMed ID: 18625455
[TBL] [Abstract][Full Text] [Related]
2. Cholinergic modulation of amyloid precursor protein processing with emphasis on M1 muscarinic receptor: perspectives and challenges in treatment of Alzheimer's disease.
Fisher A
J Neurochem; 2012 Jan; 120 Suppl 1():22-33. PubMed ID: 22122190
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic strategies in Alzheimer's disease: M1 muscarinic agonists.
Fisher A
Jpn J Pharmacol; 2000 Oct; 84(2):101-12. PubMed ID: 11128032
[TBL] [Abstract][Full Text] [Related]
4. M1 muscarinic agonists can modulate some of the hallmarks in Alzheimer's disease: implications in future therapy.
Fisher A; Pittel Z; Haring R; Bar-Ner N; Kliger-Spatz M; Natan N; Egozi I; Sonego H; Marcovitch I; Brandeis R
J Mol Neurosci; 2003; 20(3):349-56. PubMed ID: 14501019
[TBL] [Abstract][Full Text] [Related]
5. M1 muscarinic agonists as potential disease-modifying agents in Alzheimer's disease. Rationale and perspectives.
Fisher A; Michaelson DM; Brandeis R; Haring R; Chapman S; Pittel Z
Ann N Y Acad Sci; 2000; 920():315-20. PubMed ID: 11193170
[TBL] [Abstract][Full Text] [Related]
6. AF150(S) and AF267B: M1 muscarinic agonists as innovative therapies for Alzheimer's disease.
Fisher A; Brandeis R; Bar-Ner RH; Kliger-Spatz M; Natan N; Sonego H; Marcovitch I; Pittel Z
J Mol Neurosci; 2002; 19(1-2):145-53. PubMed ID: 12212772
[TBL] [Abstract][Full Text] [Related]
7. M1 muscarinic agonists target major hallmarks of Alzheimer's disease--an update.
Fisher A
Curr Alzheimer Res; 2007 Dec; 4(5):577-80. PubMed ID: 18220527
[TBL] [Abstract][Full Text] [Related]
8. Muscarinic agonists and antagonists in the treatment of Alzheimer's disease.
Greenlee W; Clader J; Asberom T; McCombie S; Ford J; Guzik H; Kozlowski J; Li S; Liu C; Lowe D; Vice S; Zhao H; Zhou G; Billard W; Binch H; Crosby R; Duffy R; Lachowicz J; Coffin V; Watkins R; Ruperto V; Strader C; Taylor L; Cox K
Farmaco; 2001 Apr; 56(4):247-50. PubMed ID: 11421251
[TBL] [Abstract][Full Text] [Related]
9. M1 agonists as a potential disease-modifying therapy for Alzheimer's disease.
Caccamo A; Fisher A; LaFerla FM
Curr Alzheimer Res; 2009 Apr; 6(2):112-7. PubMed ID: 19355845
[TBL] [Abstract][Full Text] [Related]
10. M
Russell JK; Ingram SM; Teal LB; Lindsley CW; Jones CK
ACS Chem Neurosci; 2023 Feb; 14(3):435-457. PubMed ID: 36655909
[TBL] [Abstract][Full Text] [Related]
11. Muscarinic M(1) agonists in the treatment of Alzheimer's disease.
Korczyn AD
Expert Opin Investig Drugs; 2000 Oct; 9(10):2259-67. PubMed ID: 11060805
[TBL] [Abstract][Full Text] [Related]
12. The utility of muscarinic agonists in the treatment of Alzheimer's disease.
Messer WS
J Mol Neurosci; 2002; 19(1-2):187-93. PubMed ID: 12212779
[TBL] [Abstract][Full Text] [Related]
13. A Systematic Review on Donepezil-based Derivatives as Potential Cholinesterase Inhibitors for Alzheimer's Disease.
Korabecny J; Spilovska K; Mezeiova E; Benek O; Juza R; Kaping D; Soukup O
Curr Med Chem; 2019; 26(30):5625-5648. PubMed ID: 29768996
[TBL] [Abstract][Full Text] [Related]
14. Reimagining cholinergic therapy for Alzheimer's disease.
Giacobini E; Cuello AC; Fisher A
Brain; 2022 Jul; 145(7):2250-2275. PubMed ID: 35289363
[TBL] [Abstract][Full Text] [Related]
15. M1 muscarinic acetylcholine receptors: A therapeutic strategy for symptomatic and disease-modifying effects in Alzheimer's disease?
Scarpa M; Hesse S; Bradley SJ
Adv Pharmacol; 2020; 88():277-310. PubMed ID: 32416870
[TBL] [Abstract][Full Text] [Related]
16. [Development of therapies for Alzheimer's disease based on cholinergic hypothesis-status quo and future directions].
Shimohama S
Rinsho Shinkeigaku; 2013; 53(11):1036-8. PubMed ID: 24291871
[TBL] [Abstract][Full Text] [Related]
17. Recent Developments in Tacrine-based Hybrids as a Therapeutic Option for Alzheimer's Disease.
Yamali C; Donmez S
Mini Rev Med Chem; 2023; 23(7):869-880. PubMed ID: 36464869
[TBL] [Abstract][Full Text] [Related]
18. M1 muscarinic agonists target major hallmarks of Alzheimer's disease--the pivotal role of brain M1 receptors.
Fisher A
Neurodegener Dis; 2008; 5(3-4):237-40. PubMed ID: 18322400
[TBL] [Abstract][Full Text] [Related]
19. Alzheimer's disease: the pharmacological pathway.
Allain H; Bentué-Ferrer D; Tribut O; Gauthier S; Michel BF; Drieu-La Rochelle C
Fundam Clin Pharmacol; 2003 Aug; 17(4):419-28. PubMed ID: 12914543
[TBL] [Abstract][Full Text] [Related]
20. Acetylcholinesterase inhibition in Alzheimer's Disease.
Ibach B; Haen E
Curr Pharm Des; 2004; 10(3):231-51. PubMed ID: 14754384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
